News
PHAT
5.45
+2.16%
0.12
Weekly Report: what happened at PHAT last week (1102-1106)?
Weekly Report · 1d ago
Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx
Benzinga · 11/03 13:01
Leerink Partners Sticks to Their Hold Rating for Phathom Pharmaceuticals (PHAT)
TipRanks · 11/02 16:42
Weekly Report: what happened at PHAT last week (1026-1030)?
Weekly Report · 11/02 09:42
Phathom Pharmaceuticals (PHAT) Stock Price Drops After Q3 Earnings Growth
Simply Wall St · 10/30 23:35
Phathom Pharmaceuticals (PHAT) Receives a Buy from H.C. Wainwright
TipRanks · 10/30 10:37
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Alnylam Pharma (ALNY) and Illumina (ILMN)
TipRanks · 10/30 09:50
Phathom Pharmaceuticals Q3 Revenue Jumps 71%; Reaffirms FY26 Outlook
NASDAQ · 10/29 18:55
Phathom (PHAT) Q3 2026 Earnings Call Transcript
The Motley Fool · 10/29 18:43
Phathom Pharmaceuticals Reports Q3 2026 Net Revenues of $84.7 million
NASDAQ · 10/29 17:12
Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 10/29 13:28
Phathom Pharmaceuticals reports Q3 EPS 4c, consensus 3c
TipRanks · 10/29 11:51
Phathom Pharmaceuticals backs FY26 revenue view $310M-$325M, consensus $315.24M
TipRanks · 10/29 11:50
Phathom Pharmaceuticals Non-GAAP EPS of $0.04 beats by $0.01, revenue of $84.7M misses by $0.12M
Seeking Alpha · 10/29 11:50
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
NASDAQ · 10/29 11:35
*Phathom Pharmaceuticals: Reaffirms Full-Yr 2026 Fincl Guidance >PHAT
Dow Jones · 10/29 11:04
Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est
Benzinga · 10/29 11:01
*Phathom Pharmaceuticals 3Q Loss/Shr 16c >PHAT
Dow Jones · 10/29 11:00
Press Release: Phathom Pharmaceuticals Reports -2-
Dow Jones · 10/29 11:00
Phathom Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha · 10/28 17:00
More
Webull provides a variety of real-time PHAT stock news. You can receive the latest news about Phathom Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PHAT
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults.